Guzmán M G
Departamento de Virología, Instituto de Medicina Tropical Pedro Kouri, Centro Colaborador de la OPS/OMS para el Estudio de las Enfermedades Víricas, La Habana, Cuba.
Acta Cient Venez. 1998;49 Suppl 1:38-45.
There are multiple factors responsible for the increase in the epidemics of dengue/dengue hemorrhagic fever in the tropical and subtropical regions. The characteristics of this disease, plus the absence of effective antiviral drugs; it is imperative to develop a vaccine against the dengue virus. To obtain such a vaccine, it is necessary an antigen that could bring protective immunity through life against the four dengue serotypes. Different strategies have been developed to obtain the vaccine, from the conventional one (attenuated virus), to the second and third generation of vaccines (immunisation with proteins and DNA respectively). The Envelope and the Membrane structural proteins, as well as the non structural NS1 and NS3, had been considered of major interest in the develop of the vaccine. In spite of the advances in this field, it is still much more research to be done, so it is considered that a vaccine against the dengue virus will not be available until the first decade of the next century.
热带和亚热带地区登革热/登革出血热疫情增加有多种因素。这种疾病的特点，加上缺乏有效的抗病毒药物；开发一种针对登革病毒的疫苗势在必行。为了获得这样一种疫苗，需要一种能够在一生中对四种登革热血清型产生保护性免疫的抗原。已经开发出不同的策略来获得疫苗，从传统的（减毒病毒）到第二代和第三代疫苗（分别用蛋白质和DNA进行免疫）。包膜和膜结构蛋白，以及非结构蛋白NS1和NS3，在疫苗开发中被认为具有主要意义。尽管该领域取得了进展，但仍有更多研究要做，因此人们认为在下个世纪的第一个十年之前不会有针对登革病毒的疫苗。
